Mutations in SHP2 have been found in various cancers, including [leukemias](), such as juvenile myelomonocytic leukemia (JMML), and solid tumors like lung cancer and neuroblastoma. These mutations are often associated with poorer prognoses and resistance to conventional therapies.
